Spring til hovednavigation Spring til søgning Spring til hovedindhold

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

  • Giancarlo Comi
  • , Stuart D Cook
  • , Gavin Giovannoni
  • , Kottil Rammohan
  • , Peter Rieckmann
  • , Per Soelberg Sørensen
  • , Patrick Vermersch
  • , Anthony C Hamlett
  • , Vissia Viglietta
  • , Steven J Greenberg
55 Citationer (Scopus)

Abstract

We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. MRI endpoints included mean number of T1 gadolinium-enhancing (Gd+), active T2 and combined unique (CU) lesions/patient/scan. MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. The proportion of patients with no active lesions at study end was: T1 Gd+ lesions: 86.8 and 91.0 versus 48.3 % (p 
OriginalsprogEngelsk
TidsskriftJournal of Neurology
Vol/bind260
Udgave nummer4
Sider (fra-til)1136-46
ISSN0340-5354
DOI
StatusUdgivet - 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study'. Sammen danner de et unikt fingeraftryk.

Citationsformater